New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!
Yarlagadda S.  Babu net worth and biography

Yarlagadda Babu Biography and Net Worth

Dr. Yarlagadda S. Babu Ph.D. serves as Senior Vice President - Drug Discovery of the Company. Dr. Babu joined BioCryst in 1988 and was BioCryst’s first full-time employee. Dr. Babu has served as the Company’s Vice President — Drug Discovery since 1992. In October of 2013, Dr. Babu’s title was changed to Senior Vice President of Drug Discovery. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham (“UAB”). Dr. Babu obtained his Ph.D. from the Indian Institute of Science, Bangalore and spent three years in the Laboratory of Molecular Biophysics at the University of Oxford, U.K. before joining UAB. He has over 70 publications in peer-reviewed journals, and a number of issued and pending patents to his credit.

What is Yarlagadda S. Babu's net worth?

The estimated net worth of Yarlagadda S. Babu is at least $1.70 million as of November 14th, 2022. Dr. Babu owns 298,541 shares of BioCryst Pharmaceuticals stock worth more than $1,698,698 as of December 10th. This net worth estimate does not reflect any other investments that Dr. Babu may own. Additionally, Dr. Babu receives an annual salary of $691,450.00 as Insider at BioCryst Pharmaceuticals. Learn More about Yarlagadda S. Babu's net worth.

How old is Yarlagadda S. Babu?

Dr. Babu is currently 70 years old. There are 8 older executives and no younger executives at BioCryst Pharmaceuticals. Learn More on Yarlagadda S. Babu's age.

What is Yarlagadda S. Babu's salary?

As the Insider of BioCryst Pharmaceuticals, Inc., Dr. Babu earns $691,450.00 per year. There are 4 executives that earn more than Dr. Babu. The highest earning executive at BioCryst Pharmaceuticals is Mr. Jon P. Stonehouse, CEO, President & Executive Director, who commands a salary of $1,150,000.00 per year. Learn More on Yarlagadda S. Babu's salary.

How do I contact Yarlagadda S. Babu?

The corporate mailing address for Dr. Babu and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at [email protected]. Learn More on Yarlagadda S. Babu's contact information.

Has Yarlagadda S. Babu been buying or selling shares of BioCryst Pharmaceuticals?

Yarlagadda S. Babu has not been actively trading shares of BioCryst Pharmaceuticals in the last ninety days. Most recently, Yarlagadda S. Babu sold 31,515 shares of the business's stock in a transaction on Monday, November 14th. The shares were sold at an average price of $13.88, for a transaction totalling $437,428.20. Following the completion of the sale, the insider now directly owns 298,541 shares of the company's stock, valued at $4,143,749.08. Learn More on Yarlagadda S. Babu's trading history.

Who are BioCryst Pharmaceuticals' active insiders?

BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Nancy Hutson (Director), Vincent Milano (Director), William Sheridan (Insider), and Jon Stonehouse (CEO). Learn More on BioCryst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of BioCryst Pharmaceuticals?

During the last twelve months, insiders at the biotechnology company sold shares 6 times. They sold a total of 127,370 shares worth more than $1,324,621.75. The most recent insider tranaction occured on June, 15th when Director Machelle Sanders sold 4,000 shares worth more than $31,920.00. Insiders at BioCryst Pharmaceuticals own 4.4% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.

Information on this page was last updated on 6/15/2023.

Yarlagadda S. Babu Insider Trading History at BioCryst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2022Sell31,515$13.88$437,428.20298,541View SEC Filing Icon  
12/7/2021Sell30,100$12.20$367,220.00View SEC Filing Icon  
8/25/2016Sell30,000$4.06$121,800.00111,428View SEC Filing Icon  
3/19/2015Sell12,105$10.16$122,986.80View SEC Filing Icon  
3/5/2015Sell37,400$10.59$396,066.00View SEC Filing Icon  
3/4/2015Sell10,495$10.50$110,197.50View SEC Filing Icon  
See Full Table

Yarlagadda S. Babu Buying and Selling Activity at BioCryst Pharmaceuticals

This chart shows Yarlagadda S Babu's buying and selling at BioCryst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $5.69
Low: $5.59
High: $5.82

50 Day Range

MA: $5.73
Low: $4.98
High: $6.77

2 Week Range

Now: $5.69
Low: $4.82
High: $12.07


5,120,367 shs

Average Volume

3,669,082 shs

Market Capitalization

$1.17 billion

P/E Ratio


Dividend Yield